相似文献
1
Concise drug review: azacitidine and decitabine.
Oncologist. 2013;18(5):619-24. doi: 10.1634/theoncologist.2012-0465. Epub 2013 May 13.
2
Decitabine dosage in myelodysplastic syndromes.
Blood. 2007 Aug 1;110(3):1082-3; author reply 1083. doi: 10.1182/blood-2007-03-080903.
3
The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes.
Future Oncol. 2021 Jul;17(20):2563-2571. doi: 10.2217/fon-2020-1318. Epub 2021 Mar 26.
4
Clinical update on hypomethylating agents.
Int J Hematol. 2019 Aug;110(2):161-169. doi: 10.1007/s12185-019-02651-9. Epub 2019 Apr 24.
5
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Blood. 2007 Jan 1;109(1):52-7. doi: 10.1182/blood-2006-05-021162. Epub 2006 Aug 1.
6
The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era.
Expert Rev Anticancer Ther. 2021 Sep;21(9):989-1002. doi: 10.1080/14737140.2021.1918002. Epub 2021 Apr 28.
7
Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.
Leuk Lymphoma. 2010 Dec;51(12):2250-7. doi: 10.3109/10428194.2010.524324. Epub 2010 Oct 7.
8
Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.
J Oncol Pharm Pract. 2024 Jun;30(4):721-736. doi: 10.1177/10781552241238979. Epub 2024 Mar 21.
9
Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):22-8. doi: 10.1016/j.clml.2014.04.010. Epub 2014 Jun 12.
10
[5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
Zhonghua Xue Ye Xue Za Zhi. 2013 Jun;34(6):542-3. doi: 10.3760/cma.j.issn.0253-2727.2013.06.019.
引用本文的文献
1
Disrupting the epigenetic alliance: structural insights and therapeutic strategies targeting DNMT1-UHRF1.
Funct Integr Genomics. 2025 Sep 17;25(1):194. doi: 10.1007/s10142-025-01708-9.
2
Genome-wide DNA methylation analysis identifies kidney epigenetic dysregulation in a cystinosis mouse model.
Front Cell Dev Biol. 2025 Aug 21;13:1638123. doi: 10.3389/fcell.2025.1638123. eCollection 2025.
3
Mechanism of action of decitabine in treating acute lymphoblastic leukemia.
Front Med (Lausanne). 2025 Jul 30;12:1614592. doi: 10.3389/fmed.2025.1614592. eCollection 2025.
4
DNA methylation in chronic kidney disease.
BMC Nephrol. 2025 Aug 13;26(1):455. doi: 10.1186/s12882-024-03916-0.
5
The role of DNA methylation and demethylation in bladder cancer: a focus on therapeutic strategies.
Front Oncol. 2025 Jun 26;15:1567242. doi: 10.3389/fonc.2025.1567242. eCollection 2025.
6
Wnt/Ca signaling: Dichotomous roles in regulating tumor progress (Review).
Oncol Lett. 2025 Jun 18;30(2):399. doi: 10.3892/ol.2025.15145. eCollection 2025 Aug.
7
Nanotechnology-driven Epigenetic Cancer Therapy: Precision Delivery and Sustained Release of DNA Methylation Modulators.
Yale J Biol Med. 2025 Jun 30;98(2):227-235. doi: 10.59249/GVNM8843. eCollection 2025 Jun.
8
Uncovering a Novel Role of ROR1 in the Epigenetic Regulation of Tumor Suppressor Gene CREB3L1 in Triple-Negative Breast Cancer Cells.
Biomolecules. 2025 May 16;15(5):734. doi: 10.3390/biom15050734.
9
Ubiquitin proteasome system (UPS): a crucial determinant of the epigenetic landscape in cancer.
Epigenomics. 2025 Jun;17(9):625-644. doi: 10.1080/17501911.2025.2501524. Epub 2025 May 8.
10
Recent advances on gene-related DNA methylation in cancer diagnosis, prognosis, and treatment: a clinical perspective.
Clin Epigenetics. 2025 May 5;17(1):76. doi: 10.1186/s13148-025-01884-2.
本文引用的文献
1
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Blood. 2012 Dec 6;120(24):4840-5. doi: 10.1182/blood-2012-06-436055. Epub 2012 Oct 15.
2
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
Blood. 2012 Dec 13;120(25):4945-51. doi: 10.1182/blood-2012-06-434639. Epub 2012 Aug 22.
3
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
J Clin Oncol. 2012 Jul 20;30(21):2670-7. doi: 10.1200/JCO.2011.38.9429. Epub 2012 Jun 11.
4
Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.
Br J Haematol. 2012 Jun;157(6):764-6. doi: 10.1111/j.1365-2141.2012.09076.x. Epub 2012 Mar 6.
5
Optimizing hypomethylating agents in myelodysplastic syndromes.
Curr Opin Hematol. 2012 Mar;19(2):65-70. doi: 10.1097/MOH.0b013e32834ff58a.
6
Predicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agents.
Leuk Lymphoma. 2012 May;53(5):760-2. doi: 10.3109/10428194.2011.651618. Epub 2012 Jan 31.
7
Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response.
Leuk Lymphoma. 2012 May;53(5):985-6. doi: 10.3109/10428194.2011.643408. Epub 2012 Jan 11.
8
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
Br J Haematol. 2011 Dec;155(5):599-606. doi: 10.1111/j.1365-2141.2011.08893.x. Epub 2011 Oct 8.
9
Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.
J Clin Oncol. 2011 Aug 20;29(24):3322-7. doi: 10.1200/JCO.2011.35.8135. Epub 2011 Jul 25.
10
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.
Cancer. 2011 Jun 15;117(12):2697-702. doi: 10.1002/cncr.25774. Epub 2011 Jan 10.
Zotero 插件